International Journal of Clinical Case Reports 2024, Vol.14, No.3, 117-131 http://medscipublisher.com/index.php/ijccr 130 Tenforde M., Patel M., Gaglani M., Ginde A., Douin D., Talbot H., Casey J., Mohr N., Zepeski A., McNeal T., Ghamande S., Gibbs K., Files D., Hager D., Shehu A., Prekker M., Erickson H., Gong M., Mohamed A., Johnson N., Srinivasan V., Steingrub J., Peltan I., Brown S., Martin E., Monto A., Khan A., Hough C., Busse L., Duggal A., Wilson J., Qadir N., Chang S., Mallow C., Rivas C., Babcock H., Kwon J., Exline M., Botros M., Lauring A., Shapiro N., Halasa N., Chappell J., Grijalva C., Rice T., Jones I., Stubblefield W., Baughman A., Womack K., Rhoads J., Lindsell C., Hart K., Zhu Y., Naioti E., Adams K., Lewis N., Surie D., McMorrow M., and Self W., 2022, Effectiveness of a third dose of Pfizer-BioNTech and moderna vaccines in preventing COVID-19 hospitalization among immunocompetent and immunocompromised adults - United States, August-December 2021, Morbidity and Mortality Weekly Report, 71: 118-124. https://doi.org/10.15585/mmwr.mm7104a2 PMid:35085218 PMCid:PMC9351530 Thompson M., Burgess J., Naleway A., Tyner H., Yoon S., Meece J., Olsho L., Caban-Martinez A., Fowlkes A., Lutrick K., Kuntz J., Dunnigan K., Odean M., Hegmann K., Stefanski E., Edwards L., Schaefer-Solle N., Grant L., Ellingson K., Groom H., Zunie T., Thiese M., Ivacic L., Wesley M., Lamberte J., Sun X., Smith M., Phillips A., Groover K., Yoo Y., Gerald J., Brown R., Herring M., Joseph G., Beitel S., Morrill T., Mak J., Rivers P., Harris K., Hunt D., Arvay M., Kutty P., Fry A., and Gaglani M., 2021, Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers - Eight U.S, Locations, December 2020-March 2021, Morbidity and Mortality Weekly Report, 70: 495-500. https://doi.org/10.15585/mmwr.mm7013e3 PMid:33793460 PMCid:PMC8022879 Thompson, M., Natarajan K., Irving S., Rowley E., Griggs E., Gaglani M., Klein N., Grannis S., DeSilva M., Stenehjem E., Reese S., Dickerson M., Naleway A., Han J., Konatham D., Mcevoy C., Rao S., Dixon B., Dascomb K., Lewis N., Levy M., Patel P., Liao I., Kharbanda A., Barron M., Fadel W., Grisel N., Goddard K., Yang D., Wondimu M., Murthy K., Valvi N., Arndorfer J., Fireman B., Dunne M., Embí P., Azziz‐Baumgartner E., Zerbo O., Bozio C., Reynolds S., Ferdinands J., Williams J., Link-Gelles R., Schrag S., Verani J., Ball S., and Ong T., 2022, Effectiveness of a third dose of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during periods of delta and omicron variant predominance - VISION network, 10 States, august 2021-january 2022, Morbidity and Mortality Weekly Report, 71: 139-145. https://doi.org/10.15585/mmwr.mm7104e3 PMid:35085224 PMCid:PMC9351525 Thomas S., Moreira E., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J., Marc G., Polack F., Zerbini C., Bailey R., Swanson K., Xu X., Roychoudhury S., Koury K., Bouguermouh S., Kalina W., Cooper D., Frenck R., Hammitt L., Türeci Ö., Nell H., Schaefer A., Ünal S., Yang Q., Liberator P., Tresnan D., Mather S., Dormitzer P., Şahin U., Gruber W., and Jansen K., 2021, Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine through 6 months, The New England Journal of Medicine, 385: 1761-1773. https://doi.org/10.1056/NEJMoa2110345 PMid:34525277 PMCid:PMC8461570 Wang Y., Zhang Z., Luo J., Han X., Wei Y., and Wei X., 2021, mRNA vaccine: a potential therapeutic strategy, Molecular Cancer, 20(1): 33. https://doi.org/10.1186/s12943-021-01311-z PMid:33593376 PMCid:PMC7884263 Wang Y., Zhang Y., Wu H., Huang L., Yu H., Xie Z., Zhang H., Zhang W., Chen X., Zhang H., Zhang H., Jia C., Xia S., and Wang S., 2021, Safety and immunogenicity of a quadrivalent inactivated subunit non-adjuvanted influenza vaccine: a randomized, double-blind, active-controlled phase 1 clinical trial., Vaccine, 39(29): 3871-3878. https://doi.org/10.1016/j.vaccine.2021.05.070 PMid:34088505 Watanabe A., Kani R., Iwagami M., Takagi H., Yasuhara J., and Kuno T., 2023, Assessment of efficacy and safety of mRNA COVID-19 vaccines in children aged 5 to 11 years: a systematic review and meta-analysis., JAMA pediatrics, 177(4): 384-394. https://doi.org/10.1001/jamapediatrics.2022.6243 PMid:36689319 PMCid:PMC9871947 Wu Z., Hu Y., Xu M., Chen Z., Yang W., Jiang Z., Li M., Jin H., Cui G., Chen P., Wang L., Zhao G., Ding Y., Zhao Y., and Yin W., 2021, Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial, The Lancet, Infectious Diseases, 21: 803-812. https://doi.org/10.1016/S1473-3099(20)30987-7 PMid:33548194 Xia S., Zhang Y., Wang Y., Wang H., Yang Y., Gao G., Tan W., Wu G., Xu M., Lou Z., Huang W., Xu W., Huang B., Wang H., Wang W., Zhang W., Li N., Xie Z., Ding L., You W., Zhao Y., Yang X., Liu Y., Wang Q., Huang L., Yang Y., Xu G., Luo B., Wang W., Liu P., Guo W., and Yang X., 2020, Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial, The Lancet, Infectious Diseases, 21: 39-51. https://doi.org/10.1016/S1473-3099(20)30831-8 PMid:33069281 Xu S., Yang K., Li R., and Zhang L., 2020, mRNA vaccine era-mechanisms, drug platform and clinical prospection, International Journal of Molecular Sciences, 21(18): 6582. https://doi.org/10.3390/ijms21186582 PMid:32916818 PMCid:PMC7554980
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==